Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 1.73B P/E 10.82 EPS this Y 110.50% Ern Qtrly Grth -
Income -1B Forward P/E 12.24 EPS next Y 19.10% 50D Avg Chg 3.00%
Sales 442.74M PEG 0.15 EPS past 5Y 6.41% 200D Avg Chg 1.00%
Dividend N/A Price/Book 2.45 EPS next 5Y 72.58% 52W High Chg -12.00%
Recommedations 1.70 Quick Ratio 0.80 Shares Outstanding 156.53M 52W Low Chg 14.00%
Insider Own 2.08% ROA 13.39% Shares Float 137.03M Beta 0.55
Inst Own 109.37% ROE -674.04% Shares Shorted/Prior 21.95M/15.51M Price 11.14
Gross Margin 73.78% Profit Margin -226.37% Avg. Volume 2,016,201 Target Price 18.00
Oper. Margin 3.16% Earnings Date May 2 Volume 821,302 Change -0.98%
About Ironwood Pharmaceuticals, Inc.

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Ironwood Pharmaceuticals, Inc. News
03/25/24 OPKO Health (OPK) And Entera Bio Announce Data for GLP-2
03/05/24 It’s Time! 3 Failing Biotech Stocks to Sell Right Now
02/29/24 Ironwood Pharmaceuticals Ran Up 38% Over Three Months — And Just Lost It All
02/29/24 Ironwood Pharmaceuticals Announces Positive Topline Results from Global Phase III Trial of Once-Weekly Apraglutide in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
02/23/24 Ironwood Pharmaceuticals to Present Four Abstracts at the ASPEN 2024 Nutrition Science & Practice Conference
02/17/24 Ironwood Pharmaceuticals Full Year 2023 Earnings: EPS Misses Expectations
02/16/24 Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q4 2023 Earnings Call Transcript
02/16/24 Ironwood (IRWD) Q4 Earnings Miss, Revenues Beat Marginally
02/15/24 Q4 2023 Ironwood Pharmaceuticals Inc Earnings Call
02/15/24 Ironwood Pharmaceuticals (IRWD) Reports Break-Even Earnings for Q4
02/15/24 Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results; Achieves 2023 Financial Guidance
02/05/24 Ironwood (IRWD) is on the Move, Here's Why the Trend Could be Sustainable
02/01/24 Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Investor Update Call
01/23/24 Wall Street Analysts Think Ironwood (IRWD) Could Surge 37.6%: Read This Before Placing a Bet
01/08/24 Ironwood Announces Publication in The Lancet Gastroenterology & Hepatology of New Linaclotide Phase III Data in Children and Adolescents Aged 6-17 Years with Functional Constipation
01/08/24 Ironwood Pharmaceuticals Maintains FY 2023 Financial Guidance and Announces FY 2024 Financial Guidance
01/03/24 Ironwood Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
12/12/23 Ironwood Announces the Completion of Squeeze-Out Merger With VectivBio
12/05/23 Shareholders have faith in loss-making Ironwood Pharmaceuticals (NASDAQ:IRWD) as stock climbs 9.7% in past week, taking five-year gain to 2.3%
11/30/23 Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus Management
IRWD Chatroom

User Image Cash_Drain_Tommy Posted - 4 hours ago

$IRWD I have been invested in the stock since 2018 and have been patient letting the company's strategy playout as I thought they would set themselves up to be an acquisition target. But it's been very frustrating comparing this stock's performance against average S&P 500 return or any decent company. The apraglutide readout has really screwed over the long term holders. And it doesn't help that CEO continually sells his shares at every turn, why should we believe if you don't Tommy?

User Image TeeMan123 Posted - 5 hours ago

$IRWD end of day, this mgmt team never had the guts or the brains to put so much capital on the line.. so what gives?? Who forced their hand?

User Image TeeMan123 Posted - 5 hours ago

$IRWD Give Us Chatter

User Image TeeMan123 Posted - 10 hours ago

$IRWD give us an earnings date irwd, come on, feed us some crumbs, anything will do at this stage

User Image wtzou Posted - 1 day ago

$IRWD Why did they spend $1.1B on VectivBio if they are just going to sit quietly and do nothing? Idiots. All of them, They were sitting on all that cash they should have just done stock buybacks and maybe a partner agreement on a proven P3 compound with milestones etc. Instead they straight up purchased another company. No PRs, no scientific announcements, the silence is deadly.

User Image TeeMan123 Posted - 1 day ago

$IRWD will we ever get the proverbial “chatter” on this stock or stuck in purgatory???

User Image VSTN Posted - 2 days ago

$IRWD He has to make a move soon the 1yr return is bad, the 3yr is worse..

User Image wtzou Posted - 2 days ago

$IRWD Look for big volume at close. Shorts/dark pool trades at work. Currently 1.62m

User Image raylin Posted - 2 days ago

$IRWD We can force a sale by telling Hamas and Hezbollah they are desecrating the Koran during BOD meetings. With all the ‘leadership’ eliminated, it has to be sold.

User Image VSTN Posted - 2 days ago

$IRWD Found this on the AMRN message board. Honestly, for a minute I thought they were describing Sarissa Capital…

User Image VSTN Posted - 2 days ago

$IRWD Market cap now under $1.2B….and roughly equal to what the company paid to acquire VectivBio.

User Image wtzou Posted - 2 days ago

$IRWD AbbVie (NYSE: ABBV) will announce its first-quarter 2024 financial results on Friday, April 26, 2024... IRWD should follow May 2nd. The ABBV financial report usually gives insight to USA/International Linzess/Constella revs. Also the market should appreciate the IRWD revenue, since a lot of bots misunderstood the hit we took last year to acquire VectivBio Holding AG (VECT).

User Image wtzou Posted - 2 days ago

$IRWD Balzoff should be back on this board in 10 days.... his suspensions usually last 30 days and his last "Like" was March 27th. Why do people report him he's just trying to inject a little humor into the misery......

User Image VSTN Posted - 4 days ago

$IRWD Linzess can go generic in 2029, correct?

User Image VSTN Posted - 4 days ago

$IRWD Ridiculously sick

User Image VSTN Posted - 1 week ago

$IRWD Of course we go down with the broad market and XBI, why wouldn’t we. Soon to have a lower market cap than the acquisition…

User Image idk_idk Posted - 1 week ago

Adding $IRWD here and again starting a $ZLAB position. Could take time but lets see 🤗

User Image wtzou Posted - 1 week ago

$IRWD one huge block at 4:17pm AH. 353,881 shares

User Image wtzou Posted - 1 week ago

$IRWD

User Image VSTN Posted - 1 week ago

$IRWD We have had our asses handed to us in the past 6 weeks, NOW we get to enjoy more as we trend with the market sell off…Perfect

User Image TeeMan123 Posted - 1 week ago

$IRWD mgmt isn’t out there talking, they’ve missed conference opportunities to do so, and this just builds a funding overhang on the company. Are they going to do an equity raise or not, until they drive home the message on next steps we just drift…. None of this makes any sense. It makes no sense they would buy an asset and not hit the pavement to promote the results.

User Image VSTN Posted - 1 week ago

$IRWD We are now a $1.2B market cap…If we didn’t have an acquisition, we would have OVER $1B in CASH…They really fucked this up…

User Image VSTN Posted - 2 weeks ago

$IRWD Big 4 pennies…cool

User Image Fraisedesbois Posted - 2 weeks ago

$IRWD how low can you go bitch?

User Image wtzou Posted - 2 weeks ago

$IRWD balz is gone? Probably in trouble again.

User Image wtzou Posted - 2 weeks ago

$IRWD I hope they are presenting apraglutide data at this one: (Is there any way to know if they submitted by March 20th?) RE: DDW 2024: "abstracts accepted for presentation at DDW 2024 will be made available in the DDW 2024 Meeting Planner and Mobile App around May 1." DDW 2024 will take place May 18-21, 2024, in Washington, D.C. and online. https://ddw.org/register/attendee-guide/

User Image VSTN Posted - 03/28/24

$IRWD Weak

User Image TeeMan123 Posted - 03/28/24

$IRWD sums it up pretty well… possibilities are endless, just needs to be in the hands of a large scale drug company https://www.fiercebiotech.com/biotech/ironwood-spies-new-frontier-1b-drug-exploratory-rare-disease-trial

User Image TeeMan123 Posted - 03/28/24

$IRWD ahh the wonders of a new age, long lasting and highly effective GLP2… the possibilities are endless, looks like there is a great signal in SR GI aGVHD, makes sense to try this out in in complement with drugs that impact the gut (GLP1 is the one that comes to mind)... a compound with so many possibilities does not belong in a small company like IRWD

User Image wtzou Posted - 03/28/24

$IRWD The STARGAZE results are as good as one would hope for! We have safety and efficacy for a rare patient population. It's Phase 1/2: https://investor.ironwoodpharma.com/press-releases/press-release-details/2024/Ironwood-Pharmaceuticals-Announces-Positive-Results-from-its-Phase-II-Exploratory-STARGAZE-Trial-of-Apraglutide-in-Patients-with-Steroid-Refractory-Gastrointestinal-Acute-Graft-versus-Host-Disease-SR-GI-aGVHD/default.aspx

Analyst Ratings
Wells Fargo Overweight Mar 1, 24
Piper Sandler Overweight Feb 16, 24
Craig-Hallum Buy Jan 17, 24
Wells Fargo Overweight Dec 14, 23
JMP Securities Market Outperform Sep 28, 23
Piper Sandler Overweight May 23, 23
Wells Fargo Equal-Weight Aug 16, 22
Piper Sandler Overweight Apr 22, 22
Morgan Stanley Equal-Weight Oct 12, 21
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Emany Sravan Kumar SVP, Chief Financial.. SVP, Chief Financial Officer Sep 15 Buy 8.32 36,072 300,119 188,730 09/18/23
MCCOURT Thomas A Chief Executive Offi.. Chief Executive Officer May 30 Sell 10.70 26,632 284,962 758,284 06/01/23
Silver Ronald Principal Accounting.. Principal Accounting Officer Feb 27 Sell 11.36 5,978 67,910 98,491 03/01/23
Rickard Jason SVP, Chief Operating.. SVP, Chief Operating Officer Feb 27 Sell 11.36 34,175 388,228 332,648 03/01/23
MCCOURT Thomas A Chief Executive Offi.. Chief Executive Officer Feb 27 Sell 11.36 61,231 695,584 681,354 03/01/23
Shetzline Michael CMO,SVP,Head-Res&Dru.. CMO,SVP,Head-Res&Drug Feb 27 Sell 11.36 19,322 219,498 261,586 03/01/23
John Minardo Chief Legal Officer Chief Legal Officer Feb 27 Sell 11.36 6,697 76,078 133,738 03/01/23
Davis Andrew SVP, Chief Business.. SVP, Chief Business Officer Feb 27 Sell 11.36 3,573 40,589 151,396 03/01/23
Currie Mark G Director Director Aug 11 Sell 11.78 70,000 824,600 521,758 08/15/22
Rickard Jason SVP, Chief Operating.. SVP, Chief Operating Officer Aug 08 Sell 11.65 47,477 553,107 376,730 08/10/22
Rickard Jason SVP, Chief Operating.. SVP, Chief Operating Officer Aug 08 Option 11.65 18,041 210,178 394,771 08/10/22
Currie Mark G Director Director Jun 07 Option 11.65 190,383 2,217,962 782,141 06/09/22
Currie Mark G Director Director Jun 07 Sell 12.01 190,383 2,286,500 591,758 06/09/22
- - - Mar 10 Buy 10.42 225,000 2,344,500 16,390,000 03/10/21
DENNER ALEXANDER J Director Director Mar 02 Buy 9.45 1,350,000 12,757,500 15,390,000 03/02/21
Rickard Jason SVP, Chief Operating.. SVP, Chief Operating Officer Mar 02 Sell 9.11 13,651 124,361 306,682 03/02/21
MacDonald Kelly Chief Accounting Off.. Chief Accounting Officer Dec 08 Option 9.12 5,639 51,428 98,680 12/08/20
MacDonald Kelly Chief Accounting Off.. Chief Accounting Officer Dec 08 Sell 12.5 5,639 70,488 93,041 12/08/20
Kilroy Conor SVP, GC & Secretary SVP, GC & Secretary Nov 10 Sell 10.92 836 9,129 128,833 11/10/20
Consylman Gina SVP, CFO & Treasurer SVP, CFO & Treasurer Nov 10 Sell 10.92 1,415 15,452 269,699 11/10/20